May 29, 2020
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma
May 29, 2020
Blueprint Medicines
Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors
May 29, 2020
Foundation Medicine
Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC
May 29, 2020
Zafgen
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
May 28, 2020
bluebird bio
bluebird bio Announces Live Webcast of EHA Data Review and June Investor Events